subject: Chinese Shares Fell Only 5 Percent Market Outlook Will Continue To Try To Be Brave [print this page] Yesterday Medicine Shares fall under the pursuit of money is smaller than the market, analysts believe the sector to continue strong possibility. Influenza A H1N1
by China Influenza Vaccine has been approved for human vaccination information to stimulate, in the broader market tumbled nearly 200 points yesterday, the context of the performance of Chinese stocks in a good defensive Ruoshi. At the close, down 5.01% medicine section, smaller than the overall decline in the market, especially the "Influenza" concept stocks in the smallest decline in two cities. Analysts said Chinese medicine in Ruoshi funds plate easily become a haven, after stabilizing in the broader market, the sector has continued strong possibility.
Than broader market decline Message surface, yesterday the State Food Influenza Drug Administration convened an expert review of the H1N1 influenza vaccine will, after deliberations by the Beijing Sinovac Biotech Co., Ltd. Production of influenza A H1N1 influenza vaccine has passed the expert review, and formally approved for human vaccination. At the same time, the State Food and Drug Administration has received Xinxiang Hualan to submit the application materials and will be on Sept. 1 for its production of influenza A H1N1 influenza vaccine review.
Present, there have been two schools in the school have taken place in the occasion of influenza A Epidemic Therefore, schools at all levels in September as the focus on school, the possibility of a flu outbreak has also increased. However, to some extent has been greatly enhanced for the pharmaceutical market performance of listed companies is expected, with a flu vaccine has been approved for human vaccination information released, associated financial stocks will likely rise to concern.
View from the disk, in vaccine development Hualan material will be active pursuit of the market, showed a high all day shock, eventually rose 3.9%, to close at 41.56 yuan, becoming one of very few meteoric rise to stocks.
Addition, Lukang Pharmaceutical (also a section in the absolute highlight, as the company has 21 varieties of essential drugs into the directory, so the stock will be opening a contrarian daily limit to close at 5.61 yuan. At the close, down plate Medicine 5.01%, in the context of collapse significantly stronger in the remaining sections.
Market outlook will continue to try to be brave
States Securities analyst Mao Rui Jin said, medicine has been a recent disk plate in the hot plate, because there are second bottom of macroeconomic possibility of counter-cyclical capacity of medicine, so strong consumer segment is vulnerable to money concern, a large financial haven of choice. The fact that some pharmaceutical stocks valuations are still low, but also with the concept of a hot spot, so, after stabilizing in the broader market, the sector still continue to be strong opportunities for investors to sell high, buy low, sell, take action opportunities.
In Guoxin Securities research report also referred to the medical section of the bullish for. The report pointed out that this medicine plate stagflation, Underperform in a row after 7 months, 8 months, the Chinese plate rose 4%, while the Shanghai Composite Index fell 12%. The current valuation of rational medicine plate absolute and relative low premium office history. Chinese stocks fared well in the medium-term performance as a whole, in July a new medical reform policies since the entry of the implementation period, continue to stimulate future policy, all of the advantages for companies. The current "market defense demand + stock both offensive and defensive medicine" is expected in the fourth quarter is expected to promote market early start plate.
And to fund the company's point of view, the sector's medium-term performance is also noteworthy. Long letter yesterday, said funds pharmaceutical industry researchers, major industry policy in the context of boost, and the influenza H1N1 outbreak in autumn and winter flu may concern, the recent medical gains significantly outpaced the market segment. "Although the pharmaceutical industry has accumulated in some early gains in the medium term, still have cause for concern, may be appropriate for the portfolio allocation."
Chinese Shares Fell Only 5 Percent Market Outlook Will Continue To Try To Be Brave
